Volume | 256,305 |
|
|||||
News | - | ||||||
Day High | 1.41 | Low High |
|||||
Day Low | 1.23 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
SciSparc Ltd | SPRC | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
1.35 | 1.23 | 1.41 | 1.26 | 1.37 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
1,256 | 256,305 | US$ 1.30 | US$ 334,127 | - | 1.15 - 23.66 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:31:13 | 2 | US$ 1.37 | USD |
SciSparc Ltd Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
640.94k | 521.09k | - | 2.88M | -5.12M | -9.83 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
SciSparc News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SPRC Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.22 | 1.44 | 1.19 | 1.36 | 154,495 | 0.14 | 11.48% |
1 Month | 1.85 | 2.10 | 1.15 | 1.73 | 883,297 | -0.49 | -26.49% |
3 Months | 3.80 | 6.78 | 1.15 | 2.82 | 879,046 | -2.44 | -64.21% |
6 Months | 5.39 | 14.2199 | 1.15 | 5.69 | 1,178,002 | -4.03 | -74.77% |
1 Year | 17.7008 | 23.66 | 1.15 | 5.97 | 1,930,097 | -16.34 | -92.32% |
3 Years | 182.00 | 184.08 | 1.15 | 19.27 | 1,507,277 | -180.64 | -99.25% |
5 Years | 182.00 | 184.08 | 1.15 | 19.27 | 1,507,277 | -180.64 | -99.25% |
SciSparc Description
SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company operates in the single segment of the Development of drugs based on cannabinoid molecules to be approved by an official regulatory authority. |